The tweet was deleted by the author.
But we saved everything 🙂.
Humacyte announced that Dr. Blakeslee-Carter presented the company's Symvess biologic vascular conduit at the Texas Society for Vascular and Endovascular Surgery Annual Meeting.
The presentation focused on Symvess as a treatment option for extremity arterial injury, shedding light on the evolving role of biologic conduits in vascular surgery. No additional commercial or regulatory details were provided in the announcement.
View post on X Loading...
Humacyte has recently presented interim Phase 3 V012 results for its ATEV biologic conduit for hemodialysis access in women at Kidney Week, according to a previous company announcement. The company is also scheduled to share further Phase 3 ATEV trial data in women needing hemodialysis access at ASN Kidney Week 2026, as detailed in another planned presentation. These events reflect ongoing clinical efforts around Humacyte’s biologic vascular technologies.